In NSCLC, AXL and MER may have overlapping and complementary roles; furthermore, their role in resistance to therapies and co-occurrence in the tumour microenvironment may outweigh the benefits that the development of such a concept may bring [17]. The gene discussed is MERTK; the disease is neoplasm.